Alterations in both the expression and phosphorylation of phospholemman have been reported to contribute to maladaptive cardiac hypertrophy, reduced Na+-K+ ATPase activity, arrhythmias and heart failure [121,122,123]. Here, FXYD1 is linked to heart failure.